In AML with TP53 gene mutations, TIM-3 expression is significantly increased, and CTLs exhibit characteristics of exhaustion/dysfunction, indicating that the antitumor immune response of TP53-mutated AML is insufficient, which presents a new strategy for overcoming drug resistance in AML [133]. Here, HAVCR2 is linked to acute myeloid leukemia.